Skip to main content
Equibles
PHAT logo

PHAT · Phathom Pharmaceuticals, Inc. · Metrics

Track PHAT — free

Use PHAT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PHAT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$5.74 -1.27 (-18.12%) At close · Oct 23
Russell 2000 member Rebalance outlook locked
Market Cap
$464.37M
Shares
80.90M
Volume · Oct 23 4.87M Avg daily vol (3M) 1.45M

PHAT metrics

84 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$5.74
Market cap
$464.37M

Price action

20 metrics
Price change (1W)
-17.1%
Price change (30D)
-21.4%
Price change (3M)
-49.8%
Price change (6M)
-50.9%
Price change (YTD)
-65.4%
Price change (1Y)
-57.8%
Trailing year
Price change (5Y)
-80.3%
52-week high
$18.08
52-week low
$5.74
Change from 52-week high
-68.3%
Change from 52-week low
+0.0%
Annualized volatility
66.3%
Annualized volatility (3M)
79.1%
Beta
0.5
RSI (14D)
29.5
Price vs SMA 50
-27.9%
Price vs SMA 200
-46.2%
Avg volume (3M)
1.45M
Relative volume
3.4
Average dollar volume
$11.81M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
80.90M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
1.9×
reciprocal yield 53.7%
EV / EBITDA
—
EV / EBIT
—
P / sales
1.9×
reciprocal yield 51.6%
P / book
—
FCF yield
-7.9%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-21.3%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
29.9×
reciprocal yield 3.3%
EV / revenue historical average (5Y)
29.9×
reciprocal yield 3.3%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-07-30

Profitability

9 metrics
Gross margin
82.9%
Operating margin
-17.0%
Trailing 12 months
Net margin
-41.3%
Gross profit (TTM)
$198.73M
Operating profit (TTM)
−$40.64M
Net income (TTM)
−$99.07M
Trailing 12 months
Diluted EPS (TTM)
$-1.25
FCF margin
-15.4%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$3.05
Gross profit per diluted share (TTM)
$2.54
Operating profit per diluted share (TTM)
$-0.52
EBITDA per diluted share (TTM)
$-0.52
Net income per diluted share (TTM)
$-1.27
Operating cash flow per diluted share (TTM)
$-0.47
Free cash flow per diluted share (TTM)
$-0.48
Capital expenditures per diluted share (TTM)
$0.00
R&D per diluted share (TTM)
$0.39
Stock compensation per diluted share (TTM)
$0.35
Book value per share
$-6.14

Growth

11 metrics
Revenue growth YoY
+88.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$239.66M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+15.6%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-30.3%
Debt / equity
—
Current ratio
1.9
EBITDA (TTM)
−$40.13M
Free cash flow (TTM)
−$36.91M
Quick ratio
1.9
Interest coverage
-0.6
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$17.89M
Latest balance sheet
Cash & equivalents
$182.48M
Total assets
$327.07M
Total debt
$164.59M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$36.69M
Capital expenditures (TTM)
$219,000
R&D (TTM)
$30.10M
SG&A (TTM)
$209.27M
Stock compensation (TTM)
$27.15M
R&D / revenue
12.6%
Stock compensation / revenue
11.3%

Ownership (13F)

9 metrics
13F filers
163
13F filer change QoQ
-13
Institutional ownership
90.4%
Conviction holders (share of 13F filers)
3.7%
Crowding (high-turnover and private-fund holders)
56.3%
Private-fund adviser ownership
55.3%
Active holders' share change QoQ
+0.7%
Holder tenure
14.5
Price vs estimated holder cost
-7.7%

Ownership (registered funds)

1 metrics
Index-fund ownership
10.2%

Short interest

3 metrics
Short interest
12.5%
Latest settlement · 7.4 days to cover
Days to cover
7.4d
Short-squeeze score
68 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1783183 CUSIP 71722W107 13F (30d) 16 filings 16 filers Visit website Investor relations